Table 2.

Clinical impact of RUNX1-RUNX1T1 TLs and decrease of RUNX1-RUNX1T1 TLs in relation to diagnosis as log10-transformed continuous variables during therapy, according to univariate Cox regression analysis

OSCIR
HR (95% CI)PHR (95% CI)P
TL     
 BM     
  After cycle 1 1.45 (1.04-2.01) .027 1.68 (1.21-2.34) .002 
  After cycle 2 1.28 (0.93-1.76) .134 1.33 (1.00-1.77) .049 
  At EOT 1.57 (1.14-2.17) .005 1.84 (1.29-2.61) .001 
 PB     
  After cycle 1 1.41 (0.94-2.11) .093 1.53 (1.05-2.21) .025 
  After cycle 2 1.38 (1.01-1.90) .044 1.32 (1.02-1.72) .039 
  At EOT 1.55 (1.16-2.08) .003 2.53 (1.76-3.64) <.001 
Decrease     
 BM     
  After cycle 1 1.32 (0.96-1.83) .091 1.47 (1.06-2.02) .020 
  After cycle 2 1.14 (0.84-1.56) .406 1.29 (0.98-1.70) .072 
  At EOT 1.41 (1.04-1.93) .029 1.69 (1.22-2.33) .001 
 PB     
  After cycle 1 1.52 (0.98-2.38) .064 1.57 (1.05-2.36) .028 
  After cycle 2 1.28 (0.93-1.75) .127 1.28 (0.98-1.67) .072 
  At EOT 1.45 (1.06-1.98) .019 2.40 (1.69-3.43) <.001 
OSCIR
HR (95% CI)PHR (95% CI)P
TL     
 BM     
  After cycle 1 1.45 (1.04-2.01) .027 1.68 (1.21-2.34) .002 
  After cycle 2 1.28 (0.93-1.76) .134 1.33 (1.00-1.77) .049 
  At EOT 1.57 (1.14-2.17) .005 1.84 (1.29-2.61) .001 
 PB     
  After cycle 1 1.41 (0.94-2.11) .093 1.53 (1.05-2.21) .025 
  After cycle 2 1.38 (1.01-1.90) .044 1.32 (1.02-1.72) .039 
  At EOT 1.55 (1.16-2.08) .003 2.53 (1.76-3.64) <.001 
Decrease     
 BM     
  After cycle 1 1.32 (0.96-1.83) .091 1.47 (1.06-2.02) .020 
  After cycle 2 1.14 (0.84-1.56) .406 1.29 (0.98-1.70) .072 
  At EOT 1.41 (1.04-1.93) .029 1.69 (1.22-2.33) .001 
 PB     
  After cycle 1 1.52 (0.98-2.38) .064 1.57 (1.05-2.36) .028 
  After cycle 2 1.28 (0.93-1.75) .127 1.28 (0.98-1.67) .072 
  At EOT 1.45 (1.06-1.98) .019 2.40 (1.69-3.43) <.001 

HRs were calculated for 10-fold higher RUNX1-RUNX1T1 copy numbers and 10-fold less RUNX1-RUNX1T1 decrease for both BM and PB.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal